Financiere des Professionnels Fonds d investissement inc. Acquires Shares of 70,832 ADMA Biologics Inc $ADMA

Financiere des Professionnels Fonds d investissement inc. bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the first quarter, Holdings Channel reports. The firm bought 70,832 shares of the biotechnology company’s stock, valued at approximately $638,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Summit Securities Group LLC acquired a new position in shares of ADMA Biologics in the 4th quarter valued at $29,000. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics during the third quarter worth $34,000. Optima Capital LLC bought a new stake in ADMA Biologics in the fourth quarter valued at about $36,000. Morse Asset Management Inc bought a new stake in ADMA Biologics in the fourth quarter valued at about $44,000. Finally, Nkcfo LLC bought a new stake in ADMA Biologics in the fourth quarter valued at about $47,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Down 1.1%

NASDAQ ADMA opened at $8.71 on Friday. The firm has a market cap of $2.02 billion, a P/E ratio of 12.81 and a beta of 0.73. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The stock’s 50-day moving average is $8.46 and its 200-day moving average is $12.28. ADMA Biologics Inc has a one year low of $7.21 and a one year high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. During the same quarter in the previous year, the business posted $0.11 EPS. ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ADMA. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho reduced their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Canaccord Genuity Group decreased their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.67.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple plaintiff law firms announced or reiterated the August 10, 2026 deadline for investors to seek lead plaintiff status in the ADMA securities class action, keeping the litigation in focus for shareholders. Article Title
• Neutral Sentiment: Additional notices from firms including Faruqi & Faruqi, Kahn Swick & Foti, Robbins LLP, and Rosen Law Firm reinforce that a class action is already underway, suggesting ongoing legal overhang rather than any operational update. Article Title
• Neutral Sentiment: A Yahoo Finance-linked piece and other commentary reference class actions and probes over revenue allegations, indicating the market is still processing the underlying claims against ADMA Biologics. Article Title

Insider Activity

In related news, Director Jerrold B. Grossman acquired 12,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.